Atlas Trials

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT04026100 · UNKNOWN

Trial details

NCT number
NCT04026100
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2019-12-01
Primary completion
2022-08-31
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.